Neuberger Berman Group LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.4% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 2,903,927 shares of the biopharmaceutical company’s stock after buying an additional 320,731 shares during the quarter. Neuberger Berman Group LLC’s holdings in Gilead Sciences were worth $235,276,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. FMR LLC increased its position in Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares during the period. Macquarie Group Ltd. increased its position in Gilead Sciences by 26.6% during the 3rd quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock worth $38,836,000 after buying an additional 100,741 shares during the period. Vanguard Group Inc. increased its position in Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares during the period. Northern Trust Corp increased its position in Gilead Sciences by 0.7% during the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after buying an additional 116,780 shares during the period. Finally, Toronto Dominion Bank increased its position in Gilead Sciences by 19.0% during the 2nd quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock worth $33,445,000 after buying an additional 75,364 shares during the period. Hedge funds and other institutional investors own 75.84% of the company’s stock.

In related news, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Chairman John C. Martin sold 50,000 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $83.56, for a total value of $4,178,000.00. Following the completion of the sale, the chairman now directly owns 3,046,766 shares in the company, valued at $254,587,766.96. The disclosure for this sale can be found here. Insiders sold 578,333 shares of company stock worth $44,100,508 over the last ninety days. 1.30% of the stock is currently owned by insiders.

GILD has been the topic of several recent research reports. JPMorgan Chase & Co. set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. BMO Capital Markets reissued a “hold” rating and set a $82.00 target price on shares of Gilead Sciences in a report on Friday, October 20th. Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $88.80 to $76.00 in a report on Tuesday, January 30th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price on the stock. in a report on Wednesday, January 17th. Finally, Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $86.56.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $79.32 on Friday. The firm has a market capitalization of $102,176.37, a PE ratio of 22.79, a P/E/G ratio of -1.73 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.55 and a quick ratio of 3.56. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $89.54.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.11. The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. Gilead Sciences’s revenue was down 18.7% compared to the same quarter last year. During the same period last year, the firm posted $2.70 earnings per share. equities analysts predict that Gilead Sciences, Inc. will post 6.46 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be paid a $0.57 dividend. The ex-dividend date is Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a yield of 2.87%. Gilead Sciences’s dividend payout ratio (DPR) is 59.77%.

COPYRIGHT VIOLATION NOTICE: “Neuberger Berman Group LLC Purchases 320,731 Shares of Gilead Sciences, Inc. (GILD)” was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/02/10/neuberger-berman-group-llc-purchases-320731-shares-of-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.